DAX21.206 -0,5%ESt504.935 -0,6%Top 10 Crypto11,33 +4,4%Dow39.142 -1,3%Nas16.286 -0,1%Bitcoin74.260 -0,5%Euro1,1390 +0,2%Öl67,85 +2,7%Gold3.328 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Tesla A1CX3T Novo Nordisk A3EU6F Siemens Energy ENER6Y RENK RENK73 Amazon 906866 Apple 865985 Lufthansa 823212 Volkswagen (VW) vz. 766403 Mercedes-Benz Group (ex Daimler) 710000 Allianz 840400 BASF BASF11 Infineon 623100 UnitedHealth 869561
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach EZB-Entscheid: DAX geht leichter ins lange Osterwochenende -- Netflix mit Gewinnplus -- EZB senkt Leitzins -- Siemens Energy, TSMC, NVIDIA, ASML, UnitedHealth, Hertz im Fokus
Top News
So bewegen sich die Kurse von Bitcoin, Ripple, Bitcoin Cash und Ethereum am Nachmittag So bewegen sich die Kurse von Bitcoin, Ripple, Bitcoin Cash und Ethereum am Nachmittag
Top-News der Woche: Diese Themen waren diese Woche wichtig Top-News der Woche: Diese Themen waren diese Woche wichtig
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
"600% Momentum-Strategie": Aktien hebeln und Gewinne maximieren - sichern Sie sich jetzt das Kennenlernangebot für nur 39 Euro (statt 69 Euro) im Monat!

Phaxiam Therapeutics Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
0,5840 EUR -0,0260 EUR -4,26 %
FSE
0,7100 EUR +0,0200 EUR +2,90 %
PAR
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.6,87 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3EJH8

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR001400K4B1

Phaxiam Therapeutics Aktien News

DatumMeistgelesen
GlobeNewswirePHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024
GlobeNewswirePHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area
GlobeNewswirePHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
Wer­bungPhaxiam Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswirePHAXIAM Reports Third-Quarter 2024 Financial Information
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – October 31, 2024
GlobeNewswirePHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – October 8, 2024
GlobeNewswirePHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study
GlobeNewswirePHAXIAM Provides Business and Financial Update For the First Half of 2024
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – July 1, 2024
GlobeNewswireResults of the Combined General Meeting of 28 June 2024
GlobeNewswirePHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – May 31, 2024
GlobeNewswirePHAXIAM provides Business and Financial Update for the First Quarter of 2024
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – April 30, 2024
GlobeNewswirePHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
GlobeNewswirePHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
GlobeNewswirePHAXIAM Announces 2023 Full-Year Results and Provides Business Update
GlobeNewswirePHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital - February 29, 2024
GlobeNewswirePHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital - January 31, 2024
GlobeNewswirePHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital - December 31, 2023
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital - November 30, 2023
GlobeNewswirePHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023
GlobeNewswirePHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
GlobeNewswireTP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital _September 30, 2023
Wer­bung

Phaxiam Therapeutics News

Phaxiam Therapeutics News: auf dieser Seite finden Sie alle Phaxiam Therapeutics News und Nachrichten zur Phaxiam Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Phaxiam Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Phaxiam Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.